Embodiments of this disclosure relate to techniques and systems for preparing modified cells evoking reduced immunogenic responses and application thereof. For example, hypo-immunogenic (e.g., decreased immunogenicity) and compatible stem cells may be obtained by a disruption in Transporter associated with antigen presentation 1 (TAP1) or TAP-associated glycoprotein (TAPBP) genes while maintaining normal pluripotency, karyotypes, and differentiation ability of these cells.
